News
- Author:
- Randy Dotinga
Publish date: December 22, 2023
“This policy was put in place to enhance patient safety,” Scripps said.
News
- Author:
- Randy Dotinga
Publish date: December 13, 2023
The average age at death rose 4 years during that decade, but the transition from pediatric to adult care remains a major danger zone.
News
- Author:
- Randy Dotinga
Publish date: December 12, 2023
Overall 2-year survival was 95% in a small, “robust” phase-2 trial of children and adults with sickle cell disease.
News
- Author:
- Randy Dotinga
Publish date: December 12, 2023
Interim analysis of the new study, however, finds no statistically significant boost in overall survival.
News
- Author:
- Randy Dotinga
Publish date: December 11, 2023
Canadian study indicates that real-world outcomes for patients treated for myeloma fall far short of those in clinical trials.
News
- Author:
- Randy Dotinga
Publish date: December 11, 2023
New research suggests that a polygenic score can presage how well Black pediatric patients with AML will respond to treatment.
News
- Author:
- Randy Dotinga
Publish date: December 6, 2023
Three generations of Brodsky men have forged careers in the same medical field.
News
- Author:
- Randy Dotinga
Publish date: December 4, 2023
Leaders of the American Society of Hematology preview hot topics and presentations on tap at their 2023 annual meeting.
News
- Author:
- Randy Dotinga
Publish date: November 28, 2023
The US Department of Veterans Affairs (VA) has...
News
- Author:
- Randy Dotinga
Publish date: November 22, 2023
The investigational drug’s ACR 20 response rate was typical for RA biologic treatments, and the trial’s Chinese patient population didn’t include e...
News
- Author:
- Randy Dotinga
Publish date: November 20, 2023
An experimental assay detects epigenetic features within the unique patterns and sizes of cell-free DNA found in blood, but is it better than clini...
News
- Author:
- Randy Dotinga
Publish date: November 17, 2023
Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy versus placebo in treating psoriatic arthritis and ax...
News
- Author:
- Randy Dotinga
Publish date: November 16, 2023
“Joyner said he’s ‘frustrated’ with the NIH’s ‘bureaucratic rope-a-dope,’ calling the agency’s guidelines ‘a wet blanket.’ ”
News
- Author:
- Randy Dotinga
Publish date: November 16, 2023
The level of risk for MACE rose with the dose, duration, and recency of GC use, and risk increased significantly at prednisone-equivalent doses as ...
News
- Author:
- Randy Dotinga
Publish date: November 14, 2023
Phase 4 trial offers insight into efficacy in patients whose mild cases have gotten less research attention.
